Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-07-19 | Redeye | Redeye: Enzymatica Q2 2023 - Waiting for the cold season | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-18 | Penser Access | Penser Access: Kommande studieresultat i fokus - Enzymatica | Pressreleaser | Visa Stäng |
|
||||
2023-07-18 | Enzymatica | Enzymatica AB: Kvartalsrapport Q2/2023: En spännande och viktig tid framöver | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-07-18 | Enzymatica | Enzymatica AB: Interim report Q2/2023: An exciting and important time ahead | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Penser Access | Penser Access: Interview with Enzymatica - Erik Penser Bank - May 16th 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-04 | Enzymatica | Bulletin from Annual General Meeting of Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Enzymatica | Kommuniké från årsstämma i Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-28 | Penser Access | Penser Access: Upp till bevis - Enzymatica | Pressreleaser | Visa Stäng |
|
||||
2023-04-28 | Redeye | Redeye: Enzymatica Q1 2023 - A step in the right direction | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-27 | Enzymatica | Enzymatica AB: Kvartalsrapport Q1/2023: Stark start på året - Enzymaticas tillväxtresa fortsätter enligt plan | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-04-27 | Enzymatica | Enzymatica AB: Interim report Q1/2023: Strong start to the year - Enzymatica's growth journey continues according to plan | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-04-05 | Enzymatica | Enzymatica AB: Enzymatica publishes annual report for 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-04-05 | Enzymatica | Enzymatica AB: Enzymatica publicerar årsredovisning för 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-03-31 | Enzymatica | Notice of Annual General Meeting 2023 in Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-31 | Enzymatica | Kallelse till årsstämma 2023 i Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-20 | Penser Access | Penser Access: Vår syn på bolagets potential är intakt - Enzymatica | Pressreleaser | Visa Stäng |
|
||||
2023-02-20 | Redeye | Redeye: Enzymatica Q4 2022 - Lower than our estimates | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-17 | Enzymatica | Enzymatica AB: Interim report Q4/2022: A year that laid the foundation for growth | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-02-17 | Enzymatica | Enzymatica AB: Kvartalsrapport Q4/2022: Ett år som lade grunden för tillväxt | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-12-06 | Redeye | Redeye: Redeye Initiates Coverage of Enzymatica | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-16 | Enzymatica | Enzymatica AB: Enzymatica and University of Kent launch study to explore prevention of upper respiratory virus infections in elite athletes | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-16 | Enzymatica | Enzymatica AB: Enzymatica och University of Kent startar studie för att undersöka hur elitidrottare kan förebygga virusinfektioner i de övre luftvägarna | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-03 | Penser Access | Penser Access: Inte helt ute ur coronatunneln - Enzymatica | Analyser | Visa Stäng |
|
||||
2022-11-02 | Enzymatica | Enzymatica AB: Kvartalsrapport Q3/2022: En bredare roll för ColdZyme adderar potential för framtiden | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-11-02 | Enzymatica | Enzymatica AB: Interim report Q3/2022: A broader role for ColdZyme adds potential for the future | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-11-01 | Enzymatica | Enzymatica AB: New study confirms ColdZyme stops viruses causing Covid-19 from adhering to human respiratory cells | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-01 | Enzymatica | Enzymatica AB: Ny studie bekräftar: ColdZyme hindrar virus som orsakar Covid-19 från att fästa vid mänskliga luftvägsceller | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-26 | Enzymatica | Enzymatica AB: Enzymatica announces outcome of new rights issue | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Enzymatica AB: Enzymatica announces outcome of new rights issueThe Board of Directors for Enzymatica (”Enzymatica” or ”Company”) today announces the outcome of the new rights issue with preferential rights for existing shareholders that was published on 19 July 2022 (the ”Rights issue”). The new rights issue was fully subscribed, and the Companywill receive proceeds amounting to about SEK 74.7 million before issue costs. The new rights issue was subscribed for63 percent with subscription rights and1percent without subscription rights. The remaining part of the new rights issue was subscribed for through guarantee commitments by the Company’s three largest owners. On 24 August 2022, the subscription period for the new rights issue ended.The final outcome shows that the new rights issue was fully subscribed, whereof 63percent were subscribed for with subscription rights and1 percent without subscription rights. The remaining part, corresponding to36 percent, was subscribedfor by the Company’s three largest owners according to guarantee commitments. The subscription rate of the new rights issue was SEK 5 per share and the Company will receive proceeds amounting to about SEK 74.7 million before issue costs. ”The rights issue allows us to escalate our clinical studies and is an important support for our geographic expansion. The pandemic led to substantial challenges for Enzymatica, but thanks to robust principal owners with a long-term belief in the company, we continue to build the company according to plan and spread the word about our unique product to more consumers and new markets”, said CEO Claus Egstrand. By the Rights issue the share capital will increase by SEK597,297.80 to SEK 6,570,275.77. The total number of shares in the Company will increase from 149,324,400 to 164,256,840. The last day for trading in paid-up subscribed shares (BTA) on Nasdaq First North Growth Market is expected to be 5 September 2022. The new shares are expected to be traded on Nasdaq First North Growth Market on or about 5 September 2022. The above is the final outcome of the Rights issue, thus no further press releases about the outcome of the Rights issue will be issued. Adviser For more information, please contact: Claus Egstrand, CEO, Enzymatica AB Stefan Olsson, Communication Manager, Enzymatica AB Important information This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the ”Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Canada, Japan, South Africa or Australia, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, ”qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of ”investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ”Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as ”relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it. A prospectus regarding the Rights issue described in this release has been published by the Company on 5 August 2022. This release is however not a prospectus in accordance to the definition in the Prospectus Regulation. In accordance with article 2 k of the Prospectus Regulation this press release constitutes an advertisement. Complete information regarding the Rights issue can only be obtained through the Prospectus. Enzymatica has not authorized any offer to the public of shares or rights in any other member state of the EEA. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new shares. Any investment decision in connection with the Rights issue must be made on the basis of all publicly available information relating to the Company and the Company’s shares. Such information has not been independently verified by the financial adviser. The financial adviser is acting for the Company in connection with the transaction and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the transaction or any other matter referred to herein. Information to distributors For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in Enzymatica. Each distributor is responsible for undertaking its own target market assessment in respect of the shares in Enzymatica and determining appropriate distribution channels. |
||||
2022-08-26 | Enzymatica | Enzymatica AB: Enzymatica offentliggör utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-18 | Enzymatica | Enzymatica AB: Enzymatica publishes supplementary prospectus | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-18 | Enzymatica | Enzymatica AB: Enzymatica offentliggör tilläggsprospekt | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-16 | Enzymatica | Enzymatica AB: ColdZyme blockerar även omikronvarianterna BA.4 och BA.5 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-16 | Enzymatica | Enzymatica AB: ColdZyme also blocks omicron variants BA.4 and BA.5 | Pressreleaser | Ladda ner | Visa Stäng |
|